NCT05958082Active, not recruiting
Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 7 Jul 2023
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- Henry Ford Health System
- Diseases
- Prostate cancer
- NCT number
- NCT05958082
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 1 Jan 2025 to the primary completion date, 1 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had prior germline testing.
Other
- Have somatic genetic testing that is positive for a possible germline variant.
Who the study is looking for
- Men, age greater than or equal to 18 years of age.
- Men who racially identify as black or multiracial including black
- Diagnosis of prostate cancer of any histology.
- Must meet NCCN guidelines for germline testing
- Men with very low, low or intermediate risk prostate per NCCN guidelines with a positive family history or intraductal histology. Family history here is considered significant if the patient has:
- a first degree relative with prostate cancer or more than one first/second degree relative with prostate cancer, or
- ≥3 cancers on same side of family, especially diagnoses ≤50 years of age: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, or urothelial cancer
- Men with high-risk, very-high risk (per NCCN definitions of risk groups), lymph node positive, or metastatic prostate cancer independent of family history of histology.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Henry Ford Cancer Pavilion Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.